Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil

被引:23
|
作者
Yeh, KH
Yeh, SH
Hsu, CH
Wang, TM
Ma, IF
Cheng, AL
机构
[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei 100, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan
[3] Natl Taiwan Univ, Coll Med, Canc Res Ctr, Taipei 10018, Taiwan
关键词
thymidylate synthase suppression; high-dose; 5-fluorouracil;
D O I
10.1054/bjoc.2000.1456
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have recently demonstrated that HDFL (high-dose 5-FU 2600 mg m-2 week-1 and leucovorin 500 mg m-2 week-1, weekly 24-h infusion) is highly active in the treatment of gastric cancer. To further clarify the possible mechanism underlying the improved activity of HDFL compared with conventional 5-FU regimens, we conducted in vitro studies examining the effect of these regimens on the differential regulation of thymidylate synthase (TS) in NCI-N87, a human gastric cancer cell line. The expected serum concentrations of 5-FU are 100-200 mM (lasting for less than 30 min) and 5-10 mM (tasting for 24 h) for the conventional 5-FU regimens (bolus injection or short intravenous infusion of 5-FU 370-500 mg m-2) and the HDFL regimens, respectively. Western blot analysis revealed that 24-h exposure of NCI-N87 to 2.5-10.0 mM of 5-FU resulted in a dose-dependent depletion of free TS, lasting for more than 24 h. in contrast, 30-min exposure of NCI-N87 to 200 mM of 5-FU resulted in a less than 12-h depletion of free TS. Moreover, 24-h exposure to 5-FU resulted in a higher S-phase blockade and enhanced cytotoxicity. In both modes of 5-FU treatment, the initial rapid depletion of free TS was accompanied by a rapid increment of a higher-molecular-weight TS molecule, suggesting that rapid formation of the ternary complex was the key mechanism of 5-FU action during this period. Northern blot analysis showed that the steady-state mRNA of TS was not affected by either of the schedules. We conclude that 24-h exposure of gastric cancer cells to low concentration of 5-FU resulted in better suppression of free TS, a higher degree of S-phase blockade, and enhanced cytotoxicity compared to 30-min exposure to high concentration of 5-FU. These in vitro results may help explain the improved clinical efficacy of HDFL regimens compared to conventional 5-FU regimens. (C) 2000 Cancer Research Campaign http://www.bjcancer.com.
引用
收藏
页码:1510 / 1515
页数:6
相关论文
共 50 条
  • [21] Weekly 24-h infusion of high-dose 5-flurouracil and leucovorin in patients with advanced gastric cancer
    Chen, JS
    Liu, HE
    Wang, CH
    Yang, TS
    Wang, HM
    Liau, CT
    Chang, WC
    Lin, YC
    ANTI-CANCER DRUGS, 1999, 10 (04) : 355 - 359
  • [22] Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced colorectal cancer: Taiwan experience
    Wang, WS
    Chen, PM
    Chiou, TJ
    Liu, JH
    Lin, JK
    Lin, TC
    Chen, WS
    Jiang, JK
    Yen, CC
    Fan, FS
    Hsieh, RK
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1998, 28 (01) : 16 - 19
  • [23] High-dose 5-fluorouracil with uridine-diphosphoglucose rescue increases thymidylate synthase inhibition but not 5-fluorouracil incorporation into RNA in murine tumors
    Codacci-Pisanelli, G
    Van der Wilt, CL
    Smid, K
    Noordhuis, P
    Voorn, D
    Pinedo, HM
    Peters, GJ
    ONCOLOGY, 2002, 62 (04) : 363 - 370
  • [24] Weekly high-dose 5-fluorouracil 24-hour infusion and intermediate-dose folinic acid bolus in metastatic colorectal cancer
    Stoffregen, C
    Zurborn, KH
    Boehme, V
    Schmid, A
    Lorenz, G
    Arendt, T
    Folsch, UR
    ONKOLOGIE, 1996, 19 (05): : 410 - 414
  • [25] Bimonthly 24 h infusion of high-dose 5-fluorouracil vs EAP regimen in patients with advanced gastric cancer
    Popov, I. P.
    Jelic, S. B.
    Krivokapic, Z. V.
    Jezdic, S. D.
    Pesko, P. M.
    Micev, M. T.
    Babic, D. R.
    MEDICAL ONCOLOGY, 2008, 25 (01) : 73 - 80
  • [26] Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV)
    Roehrig, Sandra
    Wein, Axel
    Albrecht, Heinz
    Konturek, Peter C.
    Reulbach, Udo
    Maennlein, Gudrun
    Wolff, Kerstin
    Ostermeier, Nicola
    Hohenberger, Werner
    Hahn, Eckhart
    Boxberger, Frank
    MEDICAL SCIENCE MONITOR, 2010, 16 (03): : CR124 - CR131
  • [27] Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients
    Cals, L
    Rixe, O
    François, E
    Favre, R
    Merad, L
    Deplanque, G
    Laadem, A
    Juin, P
    Bereder, JM
    Bernardini, D
    Herait, P
    ANNALS OF ONCOLOGY, 2004, 15 (07) : 1018 - 1024
  • [28] Intravenous weekly high-dose infusion of 5-fluorouracil and folinic acid in pretreated patients with metastatic colorectal cancer
    Lorenz, M
    StaibSebler, E
    Gog, C
    Petrowsky, H
    Encke, A
    ONKOLOGIE, 1997, 20 (03): : 222 - 225
  • [29] Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer
    Biyun Wang
    Wen Zhang
    Xiaonan Hong
    Ye Guo
    Jin Li
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 213 - 218
  • [30] Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin:: an easy-to-use and well-tolerated combination
    Delaunoit, T
    Maréhal, R
    Hendlisz, A
    Eisendrath, P
    Legendre, H
    Pector, JC
    De Becker, D
    Bleiberg, H
    ANTI-CANCER DRUGS, 2004, 15 (07) : 725 - 728